Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue
Open Access
- 2 February 2007
- journal article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 66 (7), 849-851
- https://doi.org/10.1136/ard.2007.069872
Abstract
The question of switching is not only a question of clinical practice, but has an important scientific dimension as well See linked article, p 893This publication has 26 references indexed in Scilit:
- Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?Annals Of The Rheumatic Diseases, 2007
- Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.2004
- The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.2004
- Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?2004
- Anti–tumor necrosis factor α switching in rheumatoid arthritis and juvenile chronic arthritisArthritis Care & Research, 2004
- Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effectAnnals Of The Rheumatic Diseases, 2004
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make senseAnnals Of The Rheumatic Diseases, 2003
- Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?2003
- Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution: Data from the Stockholm Tumor Necrosis Factor α Followup RegistryArthritis & Rheumatism, 2003
- [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].2002